Collegium Pharmaceutical, Inc. (COLL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
COLL Revenue Growth
Revenue Breakdown (FY 2025)
COLL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
COLL Revenue Analysis (2014–2025)
As of May 8, 2026, Collegium Pharmaceutical, Inc. (COLL) generated trailing twelve-month (TTM) revenue of $796.3 million, reflecting solid growth of +8.9% year-over-year. The most recent quarter (Q1 2026) recorded $193.5 million in revenue, down 5.8% sequentially.
Looking at the longer-term picture, COLL's 5-year compound annual growth rate (CAGR) stands at +20.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $780.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows COLL's business is primarily driven by Belbuca (36%), Xtampza ER (32%), and Nucynta IR (19%).
When compared to Healthcare sector peers including AVDL (+79.9% YoY), HRMY (+20.7% YoY), and SUPN (+16.3% YoY), COLL has underperformed the peer group in terms of revenue growth. Compare COLL vs AVDL →
COLL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| COLLCurrent | $796M | +8.9% | +20.3% | 24.0% | |
 AVDL | $169M | +79.9% | +23.4% | -25.1% | |
 HRMY | $868M | +20.7% | +40.3% | 24.0% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
COLL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $780.6M | +23.6% | $463.3M | 59.3% | $187.1M | 24.0% |
| 2024 | $631.4M | +11.4% | $377.3M | 59.8% | $169.9M | 26.9% |
| 2023 | $566.8M | +22.2% | $326.2M | 57.5% | $167.0M | 29.5% |
| 2022 | $463.9M | +67.6% | $209.5M | 45.2% | $33.3M | 7.2% |
| 2021 | $276.9M | -10.7% | $150.6M | 54.4% | $17.6M | 6.4% |
| 2020 | $310.0M | +4.5% | $179.8M | 58.0% | $56.2M | 18.1% |
| 2019 | $296.7M | +5.8% | $103.0M | 34.7% | $-23,748,000 | -8.0% |
| 2018 | $280.4M | +884.7% | $114.7M | 40.9% | $-20,685,000 | -7.4% |
| 2017 | $28.5M | +1564.3% | $25.9M | 90.9% | $-75,447,000 | -264.9% |
| 2016 | $1.7M | - | $1.5M | 87.6% | $-94,082,000 | -5498.7% |
See COLL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COLL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COLL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCOLL — Frequently Asked Questions
Quick answers to the most common questions about buying COLL stock.
Is COLL's revenue growth accelerating or slowing?
COLL maintains +8.9% revenue growth, in line with its 5-year CAGR of +20.3%. TTM revenue stands at $796M. Growth rate remains consistent with historical average.
What is COLL's long-term revenue growth rate?
Collegium Pharmaceutical, Inc.'s 5-year revenue CAGR of +20.3% reflects the sustained expansion pattern. Current YoY growth of +8.9% is near this long-term average.
How is COLL's revenue distributed by segment?
COLL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.